《Early Phase Clinical Trials for Mabs》由会员分享，可在线阅读，更多相关《Early Phase Clinical Trials for Mabs（12页珍藏版）》请在金锄头文库上搜索。
1、Early Phase Clinical Trials for MabsEaryl Pahs Celnical iTiral fsro absDM rJingLi抗药物体与向靶疗国治家重实验点室rDgu sDeevopmenltisDovercyDeevopmlnet Preclniicl aa bDANRD&早发期现阶段临床开前阶发段DVali/daiont早期临开发阶床段Cnformaotoin期临晚床发阶开段Noncliicaln:23y-C lniiac:5l8y -NID 1-N A高成功率：225% 9% 研发期：周7年ey poKntsiopulPtion aDos Biomar
2、keerIm mnugeoicntiyopPlutaio-nhealhy tvoluteres ropa tietnsT?agetrto iLgand Helahty ovulteresaMbsTagre to trceepotsreRcepors tf noo-imnune m2R eeptocrso f mimnue sytsesm2Ppoualtoin-haleht yvoutelers r potaienstTar?et togL giad nMashebalht voyutelrsep taenitsarTge tt receotorpResectpos rof nnoi-mumn
3、e多次药给负剂量荷4m/ggk维持,剂2mg/k量 gwq12 w,例 9MBCBMCeHrcpteni多：N=次1 710/05/10/020/5500gm至 DP单次给药Hecrepint单：N=次1 16/500/010250/500m/药物与临床试验登记g信息与示平公 ht台pt:/wwwch.naidrutgirals.og.rcn/aep/man i射用重注抗组HER2人化单克隆源体抗在健康志愿中的者单次给耐药性及受药学研究动Poplatuoni-eahtlyhv olteuer sropat ietn fsr FIHoTar?get otL igan Trgetato erecp
4、otsrReecptrs oo nfo-imnumn eHer2)2 DC20p+o-Brp er-B matuerB aPiettsn激活B细浆胞Ke pyionstoPupalito Done Bsomiraker mmuIognencitiyose-MDABE Laproaph csMcheainm so aftioncT argtee xperssionR ceetproocc upancyM bs affiainty Prcelnical diatIna vtio rn Iivov x EviovSattrngi dseo:OR 10ABME: Liminml anatiicatpe
5、d iolobgcai effelctlev el OAELN no:o besved adrerve sefec tevlleImmunmooudalotry mbAsrleeavn taniaml omdle pesiecs-secipifc elraivet faniiy/pttoenyc f oam A bTisse crossuerctaviityi mmneuf-unticon-realetden pdinot spsecfc imimue cnell ufcnton isasysaoDse: 0. 1gm/gk,/510t0hof the hgiesthd oseuse d in
6、p evriusoepexrminestwi th ycomnoglu smacaqusgHumn: 0.a1mg/k:g OR90%1;.5/ggk:O=1R0 Cyno%molusg mokeny: 0.1 sgmk/:gRO=1 0%0CD8:2 htre amine acio exdhacges nn ithe ocrreposndnigt rasmemnraben omdinsa.ynCmolous gonmeysk 5:0 m/gkg uHmn:a 0. 1mgkg/:Mbs:aN onlcniialcstudy pI nviro:the Tmore,het ebtertp nI
7、ivvuoelrevatn niaml amodeu Altineg anffnity u FciR nfainfiyt Tiususe rcossercaivitty umIumongnieciy utIm munootxiciy tuP armachoiketnicp sxE ivovKey ointpPospuatlinoD oes iomaBrek ImmrnouengciiyBtomirkare efDiitinoBnomairkre: A chracaetistrcit athi s bojectivelym aesurd eadne alvateu as da indinatoc
8、 orf ornam bloiogil pcocersess,apthognice ropcseess,r pohamraocogic lesprnoes so at teraheuptic inetvenrtoin .Parhmaocdyaminc Prognstoic Preictdve iSurrgaoetancDyeJ eE atl, ClinCa cnr eRes;6;74555.1Pedrciitv beimoraker dial deveelomenptiDcsoevrDyeevlompentP ercliinca l b Market NAIdDeniftiactinoP er
9、lcnicail FesiabilityAnlyaticl ValidaatoinC liinalc uaQlficaiitno Digaosisntes tBimorakerin hPas eI rialTsPhaumacrdyoamicnb oiarmerk msy paorivde porf oofdru tgagertin hbitioinan d sppuor tteh elescitno f doosefo r frther uevluatain. uoPhamarcdonyamc imrkear tusidsec nab ec nodctuedby analyiss o sfam
10、pels ndao/r image sobtinadepr ior to an afder ttreamtetn,o r bycom apiros nto a nnureattd ecntrol.ou bAiomrkea rahs an nitgera rolel t ougde thied os eecslataon deicsiios fon srubsquentepat ient sni ap ahs e trIai.l效学药及药动代学比力研较究P-K/DP尼哌和健赛尼对哌环血循CD5+细2胞制抑作比较用移植肾患者给抗C予D3抗后体单内K/PP研究D8 3000060200 004C3D
11、%150020100005 0 0 00 02 406 08 10001 20Tmi 10m剂g量组onceCtrnatoniCD3+cel l% oCcennrttaoin205+0肾移患植者给予CD3单抗抗体后P内K/DP究8研0 7 6002 .5m gm 5g 0m g1D3C性T阳巴细胞百淋分变化比cell wsithfre e CD3 %5 40 030 0 201 0 1 000 10 2000 300 40 5000 600 07 800 090010 001 100 21000 78 00c6els wilh tC3 frDee% e mh 25mg. mg 15mg005
12、4 003 0 210 0- 10049天-8 700 602 5.m g m 5g 0m g1cels with frle eD3C0 40 30 5201 0 0-1 0- 0 1 00120 3 0 0 50460 70 8090 01 10101 200481216204T2mih0-42T Hmie 0-天5Biomraekr n Phisea T rilasuEvluaae tht aessoictioa nebteenw htebi oamkerr na dlcniica lutocmoeu etDreimnepat iet enilgbilityi uDteermien the
13、 dos-eresposnere atlinsohi of app haramodyncmica mrake rcaors sanar ro setwo fodes ohcrto潜在s的病人群可找到的患患人病符合群案方要求患的人群同意参加研病究的并符合iboarmker求要患病人群的Allpts iwh cltiniac ldianogsisBimorkar Tese t+iBmarkor e-v eBoiarmkre+Exper. reTatiBomrkaer+ff OtudysEpxr.e rTaetllApt sw ti chlniicl aiagdnoissBoimrkea rTet
14、s-Bomaikrr -eevBi omraer+k+R andmoziaitno Bimaorekr+andoRmziatinOfofstu ydxEpe. rrTatetaSd.n TratexEpre .TertaStan.d rTetaAl plts iwht lcniialcdiag nsoisBiomarer kesTtatirifactoniBiomrkera+ve R nadmizotaionioBmrker -va eRadonizmaiontExep. rreaTStatd.n reTatExer. TpreatStand.Tr aeteKy oinpsPotulation
15、p Dseo iBmoakre rmImnouenigitcyWhtais im mnogeuinciyt Abiily tot provoke n aun“awtend” imunem erpsonse fomartio onfa tin-rudgantib oide, AsADs Tcel l respnses;ocy otink releasee oCmpelmet anticativno nwUntaedi mumngoneciiytis th emaorjsafety cncero nfromAb d rgs u F AD,EMA,MHLWet . rcgelauotr ayutohriies retqiuer tha ADAtb eveaulated adn croelatrdewi h tayn parmachlogoial anc/dr toxioocloigcla boervastonsiImunmogeincty in iPhsea Vir utlaly la libooligc,se vne fllu yhmuanpro tenis,c an leciti oht imsmnu erepossnes Bin dig natibnoide csna
